BioLife Solutions Inc (BLFS)

Return on total capital

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	-13,096	-27,637	-54,861	-67,346	-70,823	-106,939	-89,896	-151,179	-145,541	-114,735	-114,154	-42,146	-35,160	-22,104	-12,075	-23,900	-610	6,241	17,641	38,274
Long-term debt	US$ in thousands	4,997	7,823	10,451	15,681	17,561	20,937	23,572	23,692	23,793	24,207	6,188	6,313	6,353	6,122	5,019	916	655	—	—	—
Total stockholders’ equity	US$ in thousands	348,909	325,461	321,442	333,405	337,663	332,017	352,128	358,107	364,188	405,120	409,544	476,075	478,047	489,259	452,281	208,777	204,429	186,851	105,843	67,709
Return on total capital		-3.70%	-8.29%	-16.53%	-19.29%	-19.94%	-30.30%	-23.93%	-39.60%	-37.51%	-26.72%	-27.46%	-8.74%	-7.26%	-4.46%	-2.64%	-11.40%	-0.30%	3.34%	16.67%	56.53%

December 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-13,096K ÷ ($4,997K + $348,909K)
= -3.70%

BioLife Solutions Inc's return on total capital has been volatile over the past few years, starting strong at 56.53% as of March 31, 2020, but declining steadily thereafter. The company experienced a significant drop to -27.46% by June 30, 2022, and continued to face negative returns in subsequent periods. As of December 31, 2024, the return on total capital improved slightly to -3.70%, but it remains negative, indicating that the company may not be generating sufficient returns on the capital invested in its operations. This trend suggests that investors and stakeholders should closely monitor the company's financial performance and strategies to address the declining return on total capital.